Anti-EGFR (806) h(41BB-CD3ζ) CAR, pCDCAR1 (CAR-LC099)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-EGFR chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human EGFR. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-EGFR antibody linked to 4-1BB (CD137) and CD3ζ signaling domain. And the vector product was designed for the treatment of melanoma.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • EGFR
  • Targeting Cell Type
  • T cell
  • Targeting Diseases
  • Melanoma
  • Generation
  • Second
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral
  • Receptor Construction
  • scFv-41BB-CD3ζ
  • Discription of Signaling Cassetes
  • 41BB
    CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. On the basis of preclinical observation, this molecule can promote the persistence of antigen-specific and antigen-nonspecific chimeric antigen receptor T-cells to significantly increases antitumor activity.
    CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

  • Clone
  • 806
  • Host
  • Human
  • Target Species
  • Human
  • Gene Name
  • Epidermal Growth Factor Receptor
  • Synonyms
  • EGFR;EGFR; Epidermal Growth Factor Receptor; Epidermal Growth Factor Receptor; Receptor Tyrosine-Protein Kinase ErbB-1; Erb-B2 Receptor Tyrosine Kinase 1; Proto-Oncogene C-ErbB-1; EC 2.7.10.1; ERBB1; ERBB; HER1; Epidermal Growth Factor Receptor (Avian Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog); Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog (Avian);

Customize Your CAR Products

Customize Your CAR Products
Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
Complete CAR data FuncS

Fig.3 806 CAR T cells exhibit low or no affinity for EGFR expressed on primary astrocytes and keratinocytes.

CAR Construction : 806 scFv-28ζ Latest CAR Construction

Fig.3 806 CAR T cells exhibit low or no affinity for EGFR expressed on primary astrocytes and keratinocytes.

Individual bioluminescence was assessed in 806 and 2173 CAR T cell treated groups.

Thokala, Radhika, et al. "High-affinity chimeric antigen receptor with cross-reactive scFv to clinically relevant EGFR oncogenic isoforms." Frontiers in Oncology 11 (2021): 664236. Distributed under Open Access license CC BY 4.0, without modification.
Complete CAR data FuncS

Fig.4 Anti-tumor activity of 806 CAR T cells in in vivo.

CAR Construction : 806 scFv-28ζ Latest CAR Construction

Fig.4 Anti-tumor activity of 806 CAR T cells in in vivo.

Individual bioluminescence was assessed in 806 and 2173 CAR T cell treated groups

Thokala, Radhika, et al. "High-affinity chimeric antigen receptor with cross-reactive scFv to clinically relevant EGFR oncogenic isoforms." Frontiers in Oncology 11 (2021): 664236. Distributed under Open Access license CC BY 4.0, without modification.
Complete CAR data IHC

Fig.5 High fidelity GBM organoids demonstrate cross-reactivity of 806 CAR.

CAR Construction : 806 scFv-28ζ Latest CAR Construction

Fig.5 High fidelity GBM organoids demonstrate cross-reactivity of 806 CAR.

wtEGFR staining in both GBO lines provided additional evidence of the cross-reactive nature of the 806 CAR.

Thokala, Radhika, et al. "High-affinity chimeric antigen receptor with cross-reactive scFv to clinically relevant EGFR oncogenic isoforms." Frontiers in Oncology 11 (2021): 664236. Distributed under Open Access license CC BY 4.0, without modification.
Complete CAR data Cyt

Fig.6 In vitro characterization of 806 EGFR CAR T cells.

CAR Construction : 806 scFv-28ζ Latest CAR Construction

Fig.6 In vitro characterization of 806 EGFR CAR T cells.

Antigen specific cytolytic activity of 806 and 2173 CAR T cells against cell lines expressing EGFR and its variants.

Thokala, Radhika, et al. "High-affinity chimeric antigen receptor with cross-reactive scFv to clinically relevant EGFR oncogenic isoforms." Frontiers in Oncology 11 (2021): 664236. Distributed under Open Access license CC BY 4.0, without modification.

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-EGFR (806) h(41BB-CD3ζ) CAR, pCDCAR1 (CAR-LC099). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

CAR Vector Products

CAR Viral Particles

CAR Cell Products

TriCAR Vector Products

CAR mRNA

CAR-MA Vector Products

CAR-MA Cell Products

Online Inquiry
Products
Global Services. (Creative Biolabs Authorized)
Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter. (Creative Biolabs Authorized) NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution. (Creative Biolabs Authorized) NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
Novel Solution. (Creative Biolabs Authorized) NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
New Technology. (Creative Biolabs Authorized) NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.
Copyright © 2025 Creative Biolabs. All Rights Reserved
Cart
    Go to checkout